IMMUNOGENICITY OF MEASLES VIRUS VACCINE STRAINS

麻疹病毒疫苗株的免疫原性

• 批准号: 6161265
• 负责人: J A BEELER
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6161265
• 关键词: active immunization; age difference; antiviral antibody; child (0-11); clinical research; drug administration rate /duration; drug quality /standard; drug screening /evaluation; human subject; human therapy evaluation; immunity; measles vaccine; microorganism immunology; neutralizing antibody; thrombocytopenia

One of the major goals of the USPHS is the regional elimination of measles by the year 2000 which may be achieved due to an increase in immunization rates and implementation of a two dose schedule for measles vaccine. Adverse reactions following immunization receive additional scrutiny as wild type disease diminishes. Last year we initiated a project to investigate the biological basis for post immunization immune thrombocytopenia. To investigate the ability of measles vaccine to induce anti-platelet antibodies, mice were immunized with vaccine (MV), CEF cells, or purified IIbIIA protein. Post immunization, anti -MV, anti-CEF and anti-IIbIIIa reacted with human platelets in ELISA and in western blot, bound to a protein with a Mr of 92-105kD. Rabbit anti-IIbIIIa immunoprecipitated proteins at Mrof 180/135/100 kD from biotinylated vaccine and labeled CEF cells, consistent with reported molecular weights for the chicken vitronectin receptor. Taken together, these findings suggest that chicken cell substrate integrins in vaccine may be responsible in part for inducing anti-platelet antibodies. We are responsible for review of measles vaccine INDs and all issues related to product licensure. Use of the vaccine and changes in approved schedules should be based on data that guarantees vaccine efficacy. Our participation in these collaborative studies allows direct involvement in the evaluation of data that would support changes to the vaccine schedule. This knowledge provides the scientific basis needed for changes in approved use of licensed products and helps to provide guidance in the design of clinical trials for new measles vaccines that would be tested under IND.

USPHS的主要目标之一是在区域内消灭麻疹 到2000年，由于免疫接种的增加， 麻疹疫苗接种率和两剂接种计划的执行情况。 免疫接种后的不良反应受到额外的审查， 野生型疾病减少。 去年，我们启动了一个项目， 探讨免疫后免疫的生物学基础 血小板减少症 目的探讨麻疹疫苗诱导麻疹的能力， 抗血小板抗体，用疫苗（MV）、CEF 细胞或纯化的IIbIIA蛋白。 免疫后，抗MV、抗CEF 抗-IIbIIIa在ELISA和Western blot中与人血小板反应， 印迹，结合蛋白的Mr为92- 105 kD。 兔抗IIbIIIa 在Mrof 180/135/100 kD处从生物素化的 疫苗和标记的CEF细胞，与报告的分子量一致 鸡的玻连蛋白受体。 总的来说，这些发现 提示疫苗中鸡细胞底物整合素可能 部分负责诱导抗血小板抗体。 我们负责审查麻疹疫苗IND和所有问题 与产品许可证有关。 疫苗的使用和批准的变更 时间表应以保证疫苗效力的数据为基础。 我们 参与这些合作研究可以直接参与 评估支持疫苗变更的数据 schedule. 这些知识为变革提供了所需的科学基础 在许可产品的批准使用中， 设计新麻疹疫苗的临床试验， 在IND下测试。